Marinus Pharmaceuticals, Inc. (MRNS) Financial Statements (2024 and earlier)

Company Profile

Business Address 5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments175,336199,201240,551168,24992,326126,319
Cash and cash equivalents127,787146,904240,551168,24992,326126,319
Short-term investments47,54952,297    
Receivables5,23411,6936,3483,3983,0002,489
Inventory, net of allowances, customer advances and progress billings2,6743777104  
Inventory2,6743777104  
Other undisclosed current assets11,3659,0645,4025,2555,7656,263
Total current assets:194,609219,995252,378177,006101,091135,071
Noncurrent Assets
Property, plant and equipment3,9384,0374,2365,5205,5612,989
Other noncurrent assets2,6532,7852,9042,3152,7252,750
Total noncurrent assets:6,5916,8227,1407,8358,2865,739
TOTAL ASSETS:201,200226,817259,518184,841109,377140,810
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,19720,19323,99729,26828,27719,536
Taxes payable1,752
Employee-related liabilities6,4665,167
Accounts payable2,3024,4664,4611,6223,2994,671
Accrued liabilities17,89515,72719,53619,42819,81114,865
Debt3,850     
Other undisclosed current liabilities1,5561,3211,020(8,218)(5,167) 
Total current liabilities:25,60321,51425,01721,05023,11019,536
Noncurrent Liabilities
Long-term debt and lease obligation68,13671,49871,01872,28872,02171,756
Long-term debt, excluding current maturities68,13671,49871,01870,78070,35069,927
Liabilities, other than long-term debt2,1462,5812,6821,5081,6711,829
Accounts payable and accrued liabilities1,1561,4111,3411,5081,6711,829
Operating lease, liability9901,1701,3411,5081,6711,829
Other undisclosed noncurrent liabilities47,97646,13944,8017,9917,7727,284
Total noncurrent liabilities:118,258120,218118,50181,78781,46480,869
Total liabilities:143,861141,732143,518102,837104,574100,405
Equity
Equity, attributable to parent57,33985,085116,00082,0044,80340,405
Preferred stock  4,0434,0434,0434,0434,302
Common stock515050373737
Additional paid in capital554,587546,169542,428474,133470,222466,132
Accumulated other comprehensive income (loss)(114)74    
Accumulated deficit(497,185)(465,251)(430,521)(396,209)(469,499)(430,066)
Total equity:57,33985,085116,00082,0044,80340,405
TOTAL LIABILITIES AND EQUITY:201,200226,817259,518184,841109,377140,810

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues6,08110,3807,1622,3401,79014,186
Cost of revenue(386)(206)8(48) (1,169)
Cost of goods and services sold      (1,169)
Gross profit:5,69510,1747,1702,2921,79013,017
Operating expenses(37,134)(43,137)(36,382)(32,391)(38,556)(29,728)
Operating loss:(31,439)(32,963)(29,212)(30,099)(36,766)(16,711)
Nonoperating income (expense)2,1752,608227400(11)(1,888)
Investment income, nonoperating2,1282,5711,7445148412
Loss, foreign currency transaction, before tax      (930)
Other nonoperating income (expense)4737(1,517)(114)(95)(970)
Interest and debt expense(4,208)(4,147)(3,690)(2,634)(2,656)(1,692)
Loss from continuing operations before equity method investments, income taxes:(33,472)(34,502)(32,675)(32,333)(39,433)(20,291)
Other undisclosed income from continuing operations before income taxes    107,375  
Income (loss) from continuing operations before income taxes:(33,472)(34,502)(32,675)75,042(39,433)(20,291)
Income tax expense (benefit) 1,538 (1,637)(1,752)  
Income (loss) from continuing operations:(31,934)(34,502)(34,312)73,290(39,433)(20,291)
Income (loss) before gain (loss) on sale of properties:73,290(39,433)(20,291)
Other undisclosed net income (loss)  (228)   930
Net income (loss) attributable to parent:(31,934)(34,730)(34,312)73,290(39,433)(19,361)
Other undisclosed net income (loss) available to common stockholders, basic   336(1,656)  
Net income (loss) available to common stockholders, diluted:(31,934)(34,730)(33,976)71,634(39,433)(19,361)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(31,934)(34,730)(34,312)73,290(39,433)(19,361)
Comprehensive income (loss):(31,934)(34,730)(34,312)73,290(39,433)(19,361)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(188)74    
Comprehensive income (loss), net of tax, attributable to parent:(32,122)(34,656)(34,312)73,290(39,433)(19,361)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: